欧美综合自拍亚洲综合网_欧美黑人巨大videos异族_可乐操中文字幕_亚洲成av人福利专区网站_国产强奸视频在播放_免费无码国产在线53_最近最新的免費中文字幕_抖音免费视频素材_亚洲精品熟女一二区_国产无套粉嫩白浆在线麻豆

纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)

CLIA Kit for Plasminogen Activator Inhibitor 1 (PAI1)

SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor

  • 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) 產(chǎn)品包裝(模擬)
  • 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) 產(chǎn)品包裝(模擬)
  • 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) 實(shí)驗(yàn)結(jié)果圖
  • SCA532Hu.jpg 標(biāo)準(zhǔn)曲線圖
  • Certificate 通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證

特異性

本試劑盒用于檢測(cè)纖溶酶原激活物抑制因子1(PAI1)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。

回收率

分別于定值血清及血漿樣本中加入一定量的纖溶酶原激活物抑制因子1(PAI1)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。

樣本 回收率范圍(%) 平均回收率(%)
sodium citrate plasma(n=5) 86-97 94

精密度

精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%

線性

在定值血清及血漿樣本內(nèi)加入適量的纖溶酶原激活物抑制因子1(PAI1)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中纖溶酶原激活物抑制因子1(PAI1)含量的測(cè)定值與理論值的比率。

樣本 1:2 1:4 1:8 1:16
sodium citrate plasma(n=5) 78-98% 89-104% 98-105% 82-104%

穩(wěn)定性

經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。

實(shí)驗(yàn)流程

1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100μL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。

實(shí)驗(yàn)原理

將纖溶酶原激活物抑制因子1(PAI1)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的纖溶酶原激活物抑制因子1(PAI1)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的纖溶酶原激活物抑制因子1(PAI1)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入底物。加入底物后會(huì)產(chǎn)生輝光型光信號(hào)。發(fā)射光強(qiáng)度和樣品中的纖溶酶原激活物抑制因子1(PAI1)呈正相關(guān)。用化學(xué)發(fā)光儀測(cè)定相對(duì)光單位（RLU），計(jì)算樣品濃度。

相關(guān)產(chǎn)品

編號(hào) 適用物種：Homo sapiens (Human，人) 應(yīng)用(僅供研究使用，不用于臨床診斷！)
RPA532Hu02 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
EPA532Hu61 纖溶酶原激活物抑制因子1(PAI1)真核蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
RPA532Hu01 纖溶酶原激活物抑制因子1(PAI1)重組蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APA532Hu61 纖溶酶原激活物抑制因子1(PAI1)活性蛋白 Cell?culture;?Activity?Assays.
PAA532Hu01 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 WB; IHC; ICC; IP.
PAA532Hu02 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體 WB; IHC; ICC; IP.
LAA532Hu71 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
LAA532Hu81 纖溶酶原激活物抑制因子1(PAI1)多克隆抗體(異硫氰酸熒光素標(biāo)記) WB; IHC; ICC; IF.
MAA532Hu22 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC/IF
MAA532Hu24 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC; IP.
MAA532Hu27 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC; IP.
MAA532Hu29 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC; IP.
MAA532Hu25 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC; IP.
MAA532Hu21 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC; IP.
MAA532Hu26 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC; IP.
MAA532Hu28 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC; ICC; IP.
MAA532Hu23 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 WB; IHC
FAA532Hu04 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 Flow cytometry.
FAA532Hu02 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 Flow cytometry.
FAA532Hu06 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 Flow cytometry.
FAA532Hu08 抗纖溶酶原激活物抑制因子1(PAI1)單克隆抗體 Flow cytometry.
LAA532Hu74 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
LAA532Hu76 纖溶酶原激活物抑制因子1(PAI1)單克隆抗體(生物素標(biāo)記) WB; IHC; ICC.
MEA532Hu 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) Enzyme-linked immunosorbent assay for Antigen Detection.
SEA532Hu 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA532Hu 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) Chemiluminescent immunoassay for Antigen Detection.
LMA532Hu 纖溶酶原激活物抑制因子1(PAI1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) FLIA Kit for Antigen Detection.
PSA532Hu01 纖溶酶原激活物抑制因子1(PAI1)抗體對(duì) ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays.
KSA532Hu01 纖溶酶原激活物抑制因子1(PAI1)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) Main materials for "Do It (ELISA Kit) Yourself".

參考文獻(xiàn)

雜志 參考文獻(xiàn)
Breast Cancer Research and Treatment Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice [SpringerLink: f3w831267267p277]
Clin Appl Thromb Hemost. Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency? [Pubmed: 24203351]
Molecular Nutrition & Food Research Trans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptors [PubMed: 25546502]
Archives of Physiology and Biochemistry Activation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorder [Pubmed:26934364]
Naunyn-Schmiedeberg's Archives of Pharmacology Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression [pubmed:27447455]
Environmental toxicology and pharmacology Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats. [pubmed:28376377]
Annals of Clinical & Laboratory Science Alteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatment [pubmed:28249913]
Pharmacological reports Anti-inflammatory and antithrombotic effects of nicotine exposure in oral contraceptive-induced insulin resistance are glucocorticoid-independent [pubmed:28349880]
Haematologica Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain [Pubmed:29903766]
Biomedicine & Pharmacotherapy Puerarin prevents vascular endothelial injury through suppression of NF-κB activation in LPS-challenged human umbilical vein endothelial cells [Pubmed:29775893]
Archives of?Physical?Medicine?and Rehabilitation Impact of Regular Physical Activity on Adipocytokines and Cardiovascular Characteristics in Spinal Cord–Injured Subjects [Pubmed:29548578]
Marine Drugs Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum [Pubmed: 31027312]
Experimental and Therapeutic Medicine IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF?κB canonical pathway in LPS?stimulated alveolar epithelial cells type II [Pubmed: 31572531]
Phytomedicine Sodium aescinate significantly suppress postoperative peritoneal adhesion by inhibiting the RhoA/ROCK signaling pathway [Pubmed: 32120245]
Sci Rep Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis [Pubmed:35013379]
Phytomedicine Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: Implication for COPD drug?… [Pubmed:35121390]
留言咨詢(xún)